Intellia Therapeutics

New Capabilities

Rolling BLA submission to FDA ongoing; ~$194.6M raised in April 2026 equity offering; cash runway into at least 2028; HAELO data to be presented at EAACI Congress June 12–15, 2026 in Istanbul. Commercial launch of lonvo-z targeted for H1 2027 if approved.

On April 27, 2026, Intellia Therapeutics reported results from Phase 3 testing of lonvoguran ziclumeran (lonvo-z), a one-time in-body CRISPR gene-editing therapy for hereditary angioedema. The 80-patient randomized double-blind trial found a single IV infusion cut debilitating swelling attack rates by 87% versus placebo (weeks 5-28); 62% of patients became attack-free and stopped all preventive medications. The safety profile was clean: no serious adverse events, and infusion-related reactions, headache, and fatigue—the most common complaints—were mild or moderate.

Updated May 31